Entrada CEO Dipal Doshi sells shares for tax withholding; retains 415,664

Rhea-AI Filing Summary

Dipal Doshi, who serves as CEO and a director of Entrada Therapeutics, Inc. (TRDA), reported a sale of 8,723 shares of common stock on 09/02/2025 to cover tax withholding obligations arising from vested restricted stock units. The sale price shown is a weighted average of $5.4302 with reported trade prices ranging from $5.36 to $5.58. After this transaction, the reporting person beneficially owned 415,664 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.

Positive

• Transparent disclosure of sale purpose (tax withholding) and execution price range ($5.36–$5.58)
• Material ownership retained: 415,664 shares beneficially owned after the transaction

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider sold a small block to cover taxes; remaining stake remains substantial.

The sale of 8,723 shares appears to be a routine disposition tied to tax withholding on vested RSUs rather than a discretionary cash-raising sale. The weighted-average sale price reported is $5.4302 with transactions between $5.36 and $5.58. With 415,664 shares remaining beneficially owned directly, the reporting person retains a material equity position. This Form 4 discloses no option exercises, additional grants, or other derivative transactions. For investors, this filing documents standard insider administrative activity without additional disclosed material changes to ownership structure.

Corporate Governance Expert

TL;DR: Transaction is administrative; disclosure is complete and includes price range and purpose.

The filing clearly states the purpose (tax withholding for RSU vesting) and provides a weighted-average price plus the range of execution prices, which supports transparency. The report indicates direct beneficial ownership after the sale (415,664 shares) and is filed by a single reporting person. The signature by an attorney-in-fact is noted and dated. There are no indications of unusual trading codes or planned trading arrangements disclosed on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doshi Dipal

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		F		8,723(1)	D	$5.4302(2)	415,664	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the TRDA insider sell on Form 4?

The reporting person sold 8,723 shares of Entrada Therapeutics common stock on 09/02/2025.

Why were the TRDA shares sold by the insider?

The sale was to cover tax withholding obligations related to the vesting of previously granted restricted stock units.

At what price were the TRDA shares sold?

The weighted-average price reported is $5.4302; sales occurred at prices ranging from $5.36 to $5.58.

How many TRDA shares does the insider own after the sale?

The reporting person beneficially owned 415,664 shares following the reported transaction.

Who filed the Form 4 for TRDA and when was it signed?

The Form 4 was filed by one reporting person and the document bears a signature by Jared Cohen, as Attorney-in-Fact dated 09/04/2025.